DoorDash is accelerating its expansion beyond food delivery with a nationwide partnership to deliver Hibbett's athletic gear and the appointment of a robotics and AI veteran to its board, underscoring its ambition to become a broader commerce platform.
Levi Strauss & Co. (LEVI) posted stronger-than-expected full-year 2025 results, driven by organic growth and a strategic shift towards direct-to-consumer sales. Yet, with a muted stock performance year-to-date, investors are questioning if the iconic denim maker's transformation story is fully priced in.
Prime Minister Keir Starmer's landmark visit to Beijing marks a cautious pivot in UK-China relations, yielding agreements on tariffs, visas, and green energy. But can British businesses navigate the opportunities and challenges of re-engagement?
Fast-fashion giant Shein has been compelled to alter its public climate commitments after a German environmental watchdog issued a formal warning over 'misleading' claims. The move highlights growing scrutiny of the industry's environmental footprint.
Coveo Solutions Inc. (TSE:CVO) shattered its own records in fiscal Q3 2026, fueled by historic new bookings and surging demand for its enterprise-grade AI relevance platform. The company's focus on grounding generative AI in secure, governed data resonates as clients move from experimentation to operational deployment.
British Prime Minister Keir Starmer arrived in Shanghai Friday with over 50 business leaders, aiming to deepen UK-China commercial ties. The visit, the first by a UK premier in eight years, comes against a backdrop of renewed US skepticism over Western engagement with Beijing.
Corebridge Financial (CRBG) has launched a novel index annuity linked to the Invesco New Economy Index, offering exposure to tech themes and Bitcoin. The move comes as analysts debate whether the company's current share price fully reflects its growth potential amid mixed recent performance.
The Horatio Alger Award bestowed upon ResMed founder Dr. Peter Farrell underscores the company's decades-long leadership in sleep and respiratory care, bringing its financial performance and competitive strategy into sharper focus for investors.
Once the undisputed leader in connected fitness, Peloton Interactive is navigating a critical business reset. Faced with declining revenue, subscriber churn, and a shifting market, the company is trading rapid expansion for a strategy focused on cost control and stabilization. The core question for investors is whether its brand and ecosystem can sustain a profitable future.
A fresh round of analyst price target adjustments for European asset manager Amundi (ENXTPA:AMUN) is prompting investors to recalibrate their expectations, placing renewed scrutiny on the firm's growth trajectory in a challenging macroeconomic climate.
Amidst broader market volatility, a closer look reveals compelling opportunities in the UK's penny stock arena. We analyze three companies—Accesso Technology, ActiveOps, and Zotefoams—that combine niche market strength with evolving financial narratives for the discerning investor.
Bank of America Securities has reaffirmed its Buy rating on Hesai Group (HSAI), raising its price target to $32, citing the lidar maker's technological milestones, strategic partnership with NVIDIA, and favorable regulatory developments for autonomous driving.
H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.
UBS has increased its price target for digital transformation leader Globant to $75, forecasting a period of stabilized, if modest, growth for the IT services sector next year despite near-term revenue headwinds.
As demand for specialist education soars, private investors—from Abu Dhabi to private equity firms—are capitalizing on a strained system, drawing criticism for extracting profits from vulnerable children and cash-strapped councils.
Despite bearing the brunt of costly natural disasters, Asia-Pacific remains the world's least insured region, with a staggering $64 billion protection shortfall in 2024 alone, threatening economic stability and vulnerable communities.
Sciwind Biosciences secures Chinese approval for its GLP-1 agonist Xianyida, entering a crowded but high-stakes diabetes treatment market dominated by global giants, as the country grapples with the world's largest diabetic population.
Amprius Technologies' shares have skyrocketed over 300% in the past year, driven by excitement around its silicon-anode battery technology. However, a deep dive into the company's financials reveals a significant valuation gap, raising questions about whether the stock's momentum has outpaced its fundamentals.
Shares of antibody discovery firm AbCellera Biologics plunged 16.8% last week, reigniting debate over its true worth. While a discounted cash flow model suggests deep undervaluation, its sky-high price-to-sales ratio paints a starkly different picture, leaving investors to navigate conflicting signals in a volatile biotech market.
As the STOXX Europe 600 grapples with volatility, some investors are turning their gaze to smaller, often overlooked companies. We examine three European penny stocks, each with a market capitalization exceeding €10 million, assessing their potential amidst a challenging macroeconomic backdrop.
